Zoetis Inc. (NYSE: ZTS ) is fundamentally a companion animal business whose valuation is mostly derived from the higher-growth, higher-margin companion animal franchise, which focuses on dermatology, parasiticides, and osteoarthritis (OA) pain management for cats and dogs. While remaining aAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it e ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Zoetis Inc. is one of them. Zoetis Inc. (NYSE:ZTS) continues to strengthen its position as a global leader in animal health, with steady growth and expanding innovation. The company develops medicines, vaccines, and diagnostics for both livestock and companion animals, and its diverse product portfolio has driven consistent revenue gains of about 4.2% year over year. The corporation’s financial resilie ...

United Kingdom Companion Animal Healthcare Market Size, Share, Outlook 2025, By Global Industry Trends, Future Growth, Regional Overview till 2032shivani12 min read·Just nowJust now--Press enter or click to view image in full size“What is the current size and growth rate of the Companion Animal Healthcare Market?The global Companion Animal Healthcare Market size was valued at USD 25.46 billion in 2024 and is projected to reach USD 58.75 billion by 2032, expanding at a compound annual growth rate (CAGR) of 1 ...

Zoetis Inc. (NYSE:ZTS) is one of the best drug stocks to buy right now. Zoetis Inc. (NYSE:ZTS) announced on September 12 the adoption of a positive opinion by the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) regarding recommending the granting of marketing authorization for Portela (relfovetmab). Is Zoetis a Unique Dividend Play in the Pharma Space for 2025? Portela is a new monoclonal antibody (mAb) therapy intended to alleviate pain associated with osteoarth ...

Key Takeaways Zoetis gained CVMP support for Portela, a monoclonal antibody for feline OA pain relief.Portela offers up to 3 months of pain relief with one jab and was well-tolerated in clinical studies.Portela will complement Solensia, giving vets and owners both monthly and quarterly OA pain therapy options.Zoetis (ZTS) announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) has issued a positive opinion for its investigational monoclonal antibody (mAb) therapy, P ...

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Zoetis' Portela will be the first long-acting anti-NGF mAb therapy for cats and is designed to provide 3 months of OA pain relief. ...

Zoetis Inc. (NYSE:ZTS) is one of the 11 Best Roth IRA Stocks to Invest in Now. Zoetis Inc. (ZTS) Secures a New Five-Year $1.25 Billion Senior Unsecured Revolving Credit Facility Zoetis Inc. (NYSE:ZTS) strengthened its financial flexibility on August 27, 2025, by securing a new five-year, $1.25 billion senior unsecured revolving credit facility. The agreement replaces a 2022 facility that would have expired in 2027. The agreement was administered by JPMorgan Chase, while Barclays, Bank of America, Citiban ...

Zoetis Inc. (NYSE:ZTS) has shown resilience with a slight increase of 0.013% over the past month, despite a recent dip of 3.23% in the last 10 days.The company boasts a projected stock price increase of 21.28%, highlighting its significant growth potential and strong market position.Zoetis's financial health is solid, with a Piotroski Score of 8, indicating strong financial stability and operational efficiency.Zoetis Inc. (NYSE:ZTS) is a leading global animal health company, dedicated to the discovery, deve ...

股价表现 - 公司股价收于14979美元 单日下跌129% 表现落后于标普500指数027%的涨幅 道琼斯指数上涨043% 纳斯达克指数上涨037% [1] - 近一个月股价累计上涨183% 表现不及医疗行业654%的涨幅 且略微落后标普500指数185%的涨幅 [1] 财务预期 - 预计季度每股收益164美元 同比增长38% 季度营收预计243亿美元 同比增长156% [2] - 全年每股收益预期634美元 同比增长709% 全年营收预期951亿美元 同比增长279% [3] 估值水平 - 公司远期市盈率为2394倍 较行业平均1552倍存在溢价 [6] - 市盈增长比率为244倍 显著高于医疗药物行业平均155倍的水平 [6] 分析师评级 - 过去一个月共识每股收益预期上调008% 目前获得Zacks第三级持有评级 [5] - 医疗药物行业在Zacks行业排名中位列第87位 处于所有250多个行业的前36%分位 [7] 业绩预测调整 - 分析师预估调整反映短期业务趋势变化 正面修正通常预示积极业务前景 [3] - 预估修正与短期股价波动存在直接关联 Zacks评级系统基于这些变化提供操作建议 [4]

PresentationErin Wilson WrightEquity Analyst Good afternoon, everyone. Welcome to the Morgan Stanley Healthcare Conference. I'm Erin Wright, Healthcare Services analyst for more important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. With that, we're happy to have Zoetis with us today. So thank you. We have CEO, Kristin Peck, as well as CFO, Wetteny Jose ...